Matrix Metalloproteinase Inhibitor MMI270

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** An orally-active synthetic hydroxamic acid derivative with potential antineoplastic activity. MMI270 inhibits a broad spectrum of matrix metalloproteinases (MMPs) (specifically MMP-1, 2, 3, 9, and 13), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent may also downregulate lymphangiogenesis, resulting in decreased lymphatic system-related metastasis. (NCI04)

**Synonyms:** - (2R)-N-Hydroxy-2-[[(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methylbutanamide Monohydrochloride - (2R)-N-Hydroxy-2-[[(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methylbutanamide Monohydrochloride - CGS27023 - CGS27023A - MMI 270B CGS27023A - N-hydroxy-2(R)-[(4-methoxysulfony) (3-picolyl)-amino]-3-metylbutaneamide hydrochloride monohydrate - N-hydroxy-2(R)-[[4- methoxysulfonyl](3-picolyl)amino]-3-methylbutaneamide hydrochloride